
Sign up to save your podcasts
Or
In this episode of The Psychedelic Podcast, Paul F. Austin is joined by renowned neuroscientist Dr. Robin Carhart-Harris and microdosing policy advocate John Downs for a replay of a live event originally held on June 10th, Microdosing vs. SSRIs: What’s Happening in the Brain and Why It Matters. Find full show notes and links here: https://thethirdwave.co/podcast/episode-312b/?ref=278 Together, they explore the scientific distinctions between SSRIs and psychedelics, focusing on neuroimaging, brain entropy, emotional processing, and the REBUS model. Dr. Carhart-Harris shares key insights from landmark studies on psilocybin therapy and discusses the evidence (and limitations) around microdosing. John Downs closes the conversation with an update on the Microdosing Collective’s efforts to shift policy and expand access.
Robin Carhart-Harris, PhD is a neuropharmacologist, psychologist, and Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. He leads the Psychedelics Division at UCSF’s Neuroscape and formerly founded and led the Centre for Psychedelic Research at Imperial College London.
John Downs is Executive Director of the Microdosing Collective, advocating for responsible policy reform and legal access to microdosing. With 25 years’ experience in sales, business development, and emerging markets, John helps individuals optimize mindset, performance, and purpose. Episode Highlights:
Episode Links:
Episode Sponsors:
4.7
292292 ratings
In this episode of The Psychedelic Podcast, Paul F. Austin is joined by renowned neuroscientist Dr. Robin Carhart-Harris and microdosing policy advocate John Downs for a replay of a live event originally held on June 10th, Microdosing vs. SSRIs: What’s Happening in the Brain and Why It Matters. Find full show notes and links here: https://thethirdwave.co/podcast/episode-312b/?ref=278 Together, they explore the scientific distinctions between SSRIs and psychedelics, focusing on neuroimaging, brain entropy, emotional processing, and the REBUS model. Dr. Carhart-Harris shares key insights from landmark studies on psilocybin therapy and discusses the evidence (and limitations) around microdosing. John Downs closes the conversation with an update on the Microdosing Collective’s efforts to shift policy and expand access.
Robin Carhart-Harris, PhD is a neuropharmacologist, psychologist, and Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. He leads the Psychedelics Division at UCSF’s Neuroscape and formerly founded and led the Centre for Psychedelic Research at Imperial College London.
John Downs is Executive Director of the Microdosing Collective, advocating for responsible policy reform and legal access to microdosing. With 25 years’ experience in sales, business development, and emerging markets, John helps individuals optimize mindset, performance, and purpose. Episode Highlights:
Episode Links:
Episode Sponsors:
10,416 Listeners
1,842 Listeners
2,570 Listeners
625 Listeners
1,242 Listeners
560 Listeners
1,923 Listeners
907 Listeners
953 Listeners
465 Listeners
171 Listeners
228 Listeners
146 Listeners
113 Listeners
7,714 Listeners